GlycoMimetics initiated with a Buy at H.C. Wainwright. H.C. Wainwright analyst Edward White started GlycoMimetics with a Buy rating and $24 price target. The analyst has a positive outlook for the company’s pipeline that includes its lead candidate, rivipansel, a pan-selectin inhibitor, in Phase 3 development for the treatment of sickle cell disease vaso-occlusive crisis. GlycoMimetics, with two late stage products, one of which is licensed to Pfizer, is currently undervalued, and the stock should be bought ahead of the potential catalysts in 2019, White tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.